Click here for COVID-19 resources for your practice
SOCIAL POSTS

Indications and Important Safety Information including Boxed Warning for BOTOX® Cosmetic (onabotulinumtoxinA).
Indications and Important Safety Information for CoolSculpting® Treatment, CoolTone Treatment,
JUVÉDERM
® Collection of Fillers, KYBELLA® (deoxycholic acid) injection 10 mg/mL, LATISSE® (bimatoprost ophthalmic solution) 0.03%,
Natrelle
® Breast Implants, REVOLVE™ Advanced Adipose System, and DiamondGlow™ Treatment.

Instructions

Download social posts by clicking the Download button.


WHAT'S IN YOUR DOWNLOAD?

A zip folder with some or all of the following:

  • The file you’ve selected
  • Approved Uses and Important Safety Information (PDF)
  • Full Prescribing Information (PDF)
  • Boxed Warning and Medication Guide (PDF)
  • Instructions for Use (PDF)
  • User Manual (PDF)
  • For video assets only, you will also find instructions on how to download and loop videos

  • INSTRUCTIONS FOR USING THE LOGO, BRAND NAME, OR BRANDING IMAGES

  • The Indications and Important Safety Information must be displayed whenever the BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® Collection of Fillers, KYBELLA® (deoxycholic acid) injection 10mg/mL, LATISSE® (bimatoprost ophthalmic solution) 0.03%, Natrelle® and/or REVOLVE™ logo appears. You may use the PDF of this information in the downloaded zip file to copy and paste into your practice materials
  • The Indications and Important Safety Information should not be changed in any way. They cannot be abbreviated or altered
  • The full Product Information including Boxed Warning and Medication Guide should be given out any time a patient is treated with BOTOX® Cosmetic. These items should also accompany any material you distribute that contains the BOTOX® Cosmetic logo or brand name
  • The Patient Label should be given out any time a patient is treated with any JUVÉDERM® filler product. The Patient Label should also accompany any material you distribute that contains the logos and brand names of any JUVÉDERM® filler product
  • The full Product Information should be given out any time a patient is treated with LATISSE®. This item should also accompany any material you distribute that contains the LATISSE® logo or brand name
  • The full prescribing information should be given out any time a patient is treated with KYBELLA®. This item should also accompany any material you distribute that contains the KYBELLA® logo or brand name
  • The Patient Labeling should be reviewed with patients before deciding to move forward with surgery with Natrelle® breast implants. It should also accompany any material you distribute that contains the Natrelle® logo or brand name
  • The Important Safety Information should be reviewed with patients before deciding to move forward with surgery using the REVOLVE™ System. It should also accompany any material you distribute that contains the REVOLVE™ System logo or brand name
  • The Patient Labeling for BOTOX® Cosmetic (onabotulinumtoxinA) and/or LATISSE® (bimatoprost ophthalmic solution) 0.03% should also accompany any Natrelle® material you distribute that contains BOTOX® Cosmetic and/or LATISSE® logos or brand names
  • Social Posts
    Sort by
    Filter by
    JUVÉDERM® 2020 Harper’s Bazaar Award Winner
    Kybella® 2020 Harper’s Bazaar Award Winner
    SkinMedica® Summer Glow Promo Social Posts
    BOTOX® Cosmetic New Beauty Award
    DiamondGlow™ Event-in-a-Box Social Media Assets
    DiamondGlow™ Social Media Assets August
    DiamondGlow™ Social Media Assets July 1
    DiamondGlow™ Social Media Assets July 2
    DiamondGlow™ $50 Off
    JUVÉDERM® Lips 4
    JUVÉDERM® Lips 2
    DiamondGlow™ Practical Dermatology Social Posts
    DiamondGlow™ Keep the Glow Going Promo Social Posts
    DiamondGlow™ HCP Social Posts
    LATISSE® Summer Promo Social Posts
    TNS® Advanced+ HCP Social Posts
    TNS® Advanced+ Event in a Box Social Posts
    SkinMedica® Week 7 Social Posts
    BOTOX® Cosmetic Today’s Schedule
    BOTOX® Cosmetic Tie Dye
    BOTOX® Cosmetic Selfie Day
    BOTOX® Cosmetic Picnic
    BOTOX® Cosmetic Virtual Consultations
    JUVÉDERM® Lips 3
    JUVÉDERM® Mirror Day
    JUVÉDERM® Virtual Consultations
    BOTOX® Cosmetic Three Questions
    BOTOX® Cosmetic Five Things
    BOTOX® Cosmetic Candidate
    JUVÉDERM® VOLUMA™ XC Packaging
    JUVÉDERM® Syringe Group
    JUVÉDERM® Packaging Group
    JUVÉDERM® Now is the Time
    BOTOX® Cosmetic Redeem Your Gift Card
    JUVÉDERM® Redeem Your Gift Card
    CoolSculpting® Redeem Your Gift Card
    CoolTone™ Redeem Your Gift Card
    KYBELLA® Redeem Your Gift Card
    DiamondGlow™ Redeem Your Gift Card
    Natrelle® Redeem Your Gift Card
    Natrelle® What Does Gummy Feel Like
    Natrelle® Rock the Bikini
    Natrelle® Meet Dessiree
    Natrelle® Meet Ashley
    Natrelle® It’s What’s Inside That Counts
    Natrelle® Implant Placement
    Natrelle® Explaining the Look
    Natrelle® Did You Know Range of Fullness
    Natrelle® Breast Implant Profiles
    CoolSculpting® Make Your Re-Entrance
    CoolTone™ Make Your Re-Entrance
    Natrelle® Make Your Re-Entrance
    SkinMedica® Make Your Re-Entrance
    DiamondGlow™ Make Your Re-Entrance
    CoolSculpting® We’re Open
    CoolTone™ We’re Open
    BOTOX® Cosmetic We’re Open
    JUVÉDERM® We’re Open
    KYBELLA® We’re Open
    BOTOX® Cosmetic Sunnies
    BOTOX® Cosmetic Seashells
    BOTOX® Cosmetic Petals
    BOTOX® Cosmetic Flowers
    BOTOX® Cosmetic What Quarantine Looks Like
    BOTOX® Cosmetic We Miss You Too
    BOTOX® Cosmetic Social Distance
    BOTOX® Cosmetic Quarantine Checklist
    BOTOX® Cosmetic Asking for a Friend
    BOTOX® Cosmetic Stay Energized
    BOTOX® Cosmetic Start Anew
    BOTOX® Cosmetic See the Positive
    BOTOX® Cosmetic Rest Up
    BOTOX® Cosmetic Greet the Day
    BOTOX® Cosmetic Give Kindness
    BOTOX® Cosmetic Get Lost
    BOTOX® Cosmetic Get Crafty
    BOTOX® Cosmetic Get Artsy
    BOTOX® Cosmetic Escape
    BOTOX® Cosmetic Dress to Impress
    JUVÉDERM® Moving Rows
    JUVÉDERM® VOLUMA™ XC
    Brilliant Connections™ Evergreen Social Posts
    SkinMedica® Week 6 Social Posts
    Natrelle® Gel Rewards Program
    Natrelle® Katie Summer
    Natrelle® Jenn Summer
    Natrelle® Go Gummy 2
    Natrelle® Go Gummy 1
    Natrelle® A Range of Fullness
    DiamondGlow™ Virtual Consultations Available
    CoolSculpting® Virtual Consultations Available
    CoolSculpting® Practice Response #3
    CoolSculpting® Practice Response #2
    CoolSculpting® Practice Response #1
    CoolSculpting® My Cool Journey #2
    CoolSculpting® My Cool Journey #1
    CoolSculpting® Eat Right
    CoolSculpting® Define Your Path
    SkinMedica® Week 5 Social Posts
    SkinMedica® Week 4 Social Posts
    SkinMedica® Week 3 Social Posts
    SkinMedica® Week 2 Social Posts
    SkinMedica® Week 1 Social Posts
    DiamondGlow™ Model Social Post #1
    DiamondGlow™ Treatment Social Post
    DiamondGlow™ Diamond Tips Social Post
    DiamondGlow™ Diamond Tip Handpiece Social Post #1
    DiamondGlow™ Diamond Tip Handpiece Social Post #2
    DiamondGlow™ Model Social Post #2
    JUVÉDERM® What I’m Doing
    JUVÉDERM® Still On Point
    JUVÉDERM® Quarantine Checklist
    JUVÉDERM® Miss Lips
    JUVÉDERM® Stream It
    JUVÉDERM® Send It
    JUVÉDERM® Say It
    JUVÉDERM® Refresh It
    JUVÉDERM® Play It
    JUVÉDERM® Organize It
    JUVÉDERM® Nurture It
    JUVÉDERM® Jam It Out
    JUVÉDERM® Go For It
    JUVÉDERM® Formal Friday
    JUVÉDERM® Find the Rhythm
    JUVÉDERM® Dream It
    JUVÉDERM® Dance to the Beat
    JUVÉDERM® Dance Party
    JUVÉDERM® Create It
    JUVÉDERM® Cozy Nights
    JUVÉDERM® Catch Up
    JUVÉDERM® Boss It
    BOTOX® Cosmetic Take Time
    BOTOX® Cosmetic Stay Active
    BOTOX® Cosmetic Rise and Shine
    BOTOX® Cosmetic Moment for Yourself
    BOTOX® Cosmetic Get Organized
    BOTOX® Cosmetic Fresh Start
    BOTOX® Cosmetic Find Your Zen
    BOTOX® Cosmetic Celebrate the Little Things
    BOTOX® Cosmetic Be Inspired
    BOTOX® Cosmetic We Thank You
    BOTOX® Cosmetic We’re All In This Together
    BOTOX® Cosmetic Take Care Of Yourself
    BOTOX® Cosmetic Focus On Today
    JUVÉDERM® We Thank You
    JUVÉDERM® We’re All In This Together
    JUVÉDERM® Take Care of Yourself
    JUVÉDERM® Focus On Today
    BOTOX® Cosmetic Stay Connected
    BOTOX® Cosmetic Check In
    BOTOX® Cosmetic Be Safe
    JUVÉDERM® You Are Amazing
    JUVÉDERM® Take Care
    JUVÉDERM® Learn It #9
    JUVÉDERM® Learn It #8
    JUVÉDERM® Learn It #7
    JUVÉDERM® Learn It #6
    JUVÉDERM® Learn It #5
    JUVÉDERM® Learn It #4
    JUVÉDERM® Learn It #3
    JUVÉDERM® Learn It #2
    JUVÉDERM® Learn It #1
    Hyaluronic What?!
    Can I Save on JUVÉDERM®?
    BOTOX® Cosmetic Thinking About Crow’s Feet
    BOTOX® Cosmetic There is ONLY ONE
    BOTOX® Cosmetic Temporarily Smooths
    BOTOX® Cosmetic Spring Florals
    BOTOX® Cosmetic Spring Blooms
    BOTOX® Cosmetic Since 2002
    BOTOX® Cosmetic ONE Approved Forehead Lines
    BOTOX® Cosmetic Got Moderate to Severe Forehead Lines
    BOTOX® Cosmetic FDA Label States
    BOTOX® Cosmetic Ask For It By Name
    BOTOX® Cosmetic About 10 Minutes
    BOTOX® Cosmetic 24-48 Hours Indication Education
    BOTOX® Cosmetic 10 Minute Treatment Results
    JUVÉDERM® Ultra XC Social Post
    JUVÉDERM® XC Social Post
    JUVÉDERM® VOLUMA™ XC Social Post
    JUVÉDERM® VOLUMA™ XC Social Post_2
    BOTOX® Cosmetic Book Appointment Reminder
    BOTOX® Cosmetic Take Time for Your Selfie
    BOTOX® Cosmetic See the Vial Watercolor
    BOTOX® Cosmetic See the Vial Rocks
    BOTOX® Cosmetic Indications
    BOTOX® Cosmetic Dancing Vials
    BOTOX® Cosmetic There Is Only ONE You
    Video Restrictions
    This video is approved for in-office use ONLY. Usage rights are NOT extended to external promotions outside the office, including social media, broadcast, and print promotions.
    See Approved Uses, Important Safety Information, and Prescribing Information
    EXPAND

    Indications, Important Safety Information and Prescribing Information

    BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

    Indications

    BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

    - Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

    - Moderate to severe lateral canthal lines associated with orbicularis oculi activity

    - Moderate to severe forehead lines associated with frontalis activity

    IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

    WARNING: DISTANT SPREAD OF TOXIN EFFECT

    Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

    CONTRAINDICATIONS

    BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

    WARNINGS AND PRECAUTIONS

    Lack of Interchangeability Between Botulinum Toxin Products

    The potency units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

    Spread of Toxin Effect

    Please refer to Boxed Warning for Distant Spread of Toxin Effect.

    No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

    Serious Adverse Reactions With Unapproved Use

    Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

    Hypersensitivity Reactions

    Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

    Cardiovascular System

    There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

    Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders

    Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).

    Dysphagia and Breathing Difficulties

    Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

    Pre-existing Conditions at the Injection Site

    Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

    Dry Eye in Patients Treated With BOTOX® Cosmetic

    There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

    Human Albumin and Transmission of Viral Diseases

    This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

    ADVERSE REACTIONS

    The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

    The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

    The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%) and eyelid ptosis (2%).

    DRUG INTERACTIONS

    Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

    The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by

    administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

    Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after

    administration of BOTOX® Cosmetic.

    USE IN SPECIFIC POPULATIONS

    There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

    Please see BOTOX® Cosmetic full Prescribing Information including Boxed Warning and Medication Guide.


    CoolSculpting® Treatment Important Information

    Indications

    The CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.

    Important Safety Information

    CoolSculpting® is contraindicated in patients with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

    Ask your patient about any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

    During the procedure patients may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental or submandibular area treatment.

    Rare side effects may also occur. Paradoxical hyperplasia (visibly enlarged tissue volume in the treated area) may develop 2-5 months after treatment and requires surgical intervention for correction.

    As with any medical procedure, a consultation should be done by a licensed healthcare professional to determine if the patient is a candidate for treatment. Consult the CoolSculpting® System User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects. Treatment applications that deviate from the guidelines are not recommended.


    CoolTone™

    Indications

    The CoolTone™ device is indicated for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone™ is also indicated for strengthening, toning, and firming of buttocks and thighs.

    Important Safety Information

    CoolTone™ treatment is contraindicated in placing the active applicator over metal, electrical, or electronic implants/devices in the treatment area like cardiac pacemakers, cochlear implants, intrathecal pumps, implanted defibrillators, implanted neurostimulators, drug pumps, or hearing aids.

    CoolTone™ is also contraindicated in placing the active applicator over menstruating uterus, over areas of the skin that lack normal sensation, and in patients with fever, malignant tumor, hemorrhagic conditions, epilepsy, recent surgical procedure, pulmonary insufficiency, or pregnancy.

    CoolTone™ should be used with caution in patients with Graves’ disease, active bleeding disorders, or seizure disorders.

    Women who are close to menstruation may find that it comes sooner, or cramping is increased or intensified with CoolTone™ treatments, therefore, it is recommended to not undergo treatment during this time of the month.

    CoolTone™ should not be used in the heart or head areas, areas of growth plate, over the carotid sinus nerves, or over the neck or mouth. CoolTone™ should not be applied over swollen, infected, inflamed areas or skin eruptions. Caution should be used for patients with suspected or diagnosed heart problems.

    Ensure that persons with pacemakers are not present in vicinity of the device during treatment.

    Common adverse effects may include, but may not be limited to muscular pain, temporary muscle spasm, temporary joint or tendon pain, and local erythema or skin redness.

    Consult the CoolTone™ User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects. Treatment applications that deviate from the guidelines are not recommended.


    JUVÉDERM® Collection of Fillers Important Information

    INDICATIONS

    JUVÉDERM® VOLUMA™ XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.

    JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

    JUVÉDERM® VOLLURE™ XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

    JUVÉDERM® Ultra XC injectable gel is indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

    JUVÉDERM® VOLBELLA™ XC injectable gel is indicated for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

    WARNINGS

    • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
    • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

    PRECAUTIONS

    • In order to minimize the risk of potential complications, these products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy
    • Healthcare professionals are encouraged to discuss the potential risks of soft-tissue injections with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications
    • The safety and effectiveness for the treatment of anatomic regions other than the mid-face with JUVÉDERM® VOLUMA™ XC; facial wrinkles and folds with JUVÉDERM® Ultra XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® VOLLURE™ XC; and the lips and perioral area with JUVÉDERM® Ultra XC and JUVÉDERM® VOLBELLA™ XC have not been established in controlled clinical studies
    • As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Follow standard precautions associated with injectable materials
    • The safety for use during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
    • The safety for use of JUVÉDERM® VOLUMA™ XC in patients under 35 or over 65 years, JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC in patients under 18 years, and JUVÉDERM® VOLLURE™ XC and JUVÉDERM® VOLBELLA™ XC in patients under 22 years has not been established
    • Use with caution in patients on immunosuppressive therapy
    • Patients who are using products that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
    • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or if these products are administered before the skin has healed completely, there is a possible risk of an inflammatory reaction at the treatment site
    • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
    • The safety of JUVÉDERM® VOLUMA™ XC injectable gel for use in patients with very thin skin in the mid-face has not been established
    • Patients may experience late onset nodules with use of dermal fillers, including JUVÉDERM® VOLUMA™ XC
    • Patients may experience late onset adverse events with use of dermal fillers

    ADVERSE EVENTS

    The most commonly reported side effects for JUVÉDERM® injectable gels were injection-site redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For

    JUVÉDERM® VOLBELLA™ XC, dryness was also reported. For JUVÉDERM® VOLUMA™ XC, side effects were predominantly moderate in severity, with duration of 2 to 4 weeks; for JUVÉDERM® Ultra XC,

    JUVÉDERM® Ultra Plus XC, or JUVÉDERM® VOLLURE™ XC, they were mostly mild or moderate in severity, with duration of 14 days or less; and for JUVÉDERM® VOLBELLA™ XC, they were predominantly mild or moderate, with duration of 30 days or less.

    To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan at 1-800-433-8871. Please visit JuvedermDFU.com for more information.

    Products in the JUVÉDERM® Collection are available by prescription only.


    KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

    INDICATION

    KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

    The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    KYBELLA® is contraindicated in the presence of infection at the injection sites.

    WARNINGS AND PRECAUTIONS

    Marginal Mandibular Nerve Injury

    Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

    Dysphagia

    Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

    Injection-Site Hematoma/Bruising

    In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

    Risk of Injecting into or in Proximity to Vulnerable Anatomic Structures

    To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

    Injection Site Alopecia

    Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

    Injection Site Ulceration and Necrosis

    Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

    ADVERSE REACTIONS

    The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

    Please see KYBELLA® full Prescribing Information.


    LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information

    Indication

    LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.

    Important Safety Information

    Contraindications: LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.

    Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.

    Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.

    Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been

    reported to be reversible upon discontinuation of bimatoprost in most patients.

    There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.

    LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

    Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients.

    Postmarketing Experience: The following adverse reactions have been identified during postapproval use of LATISSE®: dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred.

    Please see LATISSE® full Prescribing Information.


    Natrelle® Breast Implants Important Information

    INDICATIONS

    Natrelle® Breast Implants are indicated for women for the following:

    • Breast augmentation for women at least 22 years old for silicone-filled implants.
      Breast augmentation for women at least 18 years old for saline-filled implants.
      Breast augmentation includes primary breast augmentation to increase breast size, as well as revision surgery to correct or improve the result of a primary breast augmentation surgery.
    • Breast reconstruction. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the result of a primary breast reconstruction surgery.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    Breast implant surgery should not be performed in:

    • Women with active infection anywhere in their body.
    • Women with existing cancer or precancer of their breast who have not received adequate treatment for those conditions.
    • Women who are currently pregnant or nursing.

    WARNINGS

    • Breast implants are not lifetime devices or necessarily a one-time surgery.
    • Avoid damage during surgery: Care should be taken to avoid the use of excessive force and to minimize handling of the implant. Use care when using surgical instruments in proximity with the breast implant. For more information, please see the full Directions for Use.

    PRECAUTIONS

    Safety and effectiveness have not been established in patients with the following:

    • Autoimmune diseases (eg, lupus and scleroderma).
    • A compromised immune system (eg, currently receiving immunosuppressive therapy).
    • Planned chemotherapy following breast implant placement.
    • Planned radiation therapy to the breast following breast implant placement.
    • Conditions or medications that interfere with wound healing and blood clotting.
    • Reduced blood supply to breast tissue.
    • Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders. Please discuss any history of mental health disorders prior to surgery. Patients with a diagnosis of depression, or other mental health disorders, should wait until resolution or stabilization of these conditions prior to undergoing breast implantation surgery.

    ADVERSE EVENTS

    Key adverse events are reoperation, implant removal with or without replacement, implant rupture with silicone-filled implants, implant deflation with saline-filled implants, and capsular contracture Baker Grade III/IV.

    Other potential adverse events that may occur with breast implant surgery include: asymmetry, breast pain, breast/skin sensation changes, capsular calcification, delayed wound healing, hematoma, hypertrophic scarring/ scarring, implant extrusion, implant malposition, implant palpability/visibility, infection, nipple complications, redness, seroma, swelling, tissue/skin necrosis, wrinkling/rippling.

    For more information see the full Directions for Use at www.allergan.com/labeling/usa.htm. To report a problem with Natrelle® Breast Implants, please call Allergan at 1-800-433-8871.

    Natrelle® Breast Implants are available by prescription only.


    REVOLVE™ Advanced Adipose System

    Indications and Important Safety Information

    INDICATIONS

    The REVOLVE™ Advanced Adipose System (REVOLVE™ System) is used for aspiration, harvesting, filtering, and transferring of autologous adipose tissue for aesthetic body contouring. This system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is only to be used without any additional manipulation. REVOLVE™ System is intended for use in the following surgical specialties when the aspiration of soft tissue is desired: plastic and reconstructive surgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, orthopedic surgery, gynecological surgery, thoracic surgery, and laparoscopic surgery.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    Contraindications to autologous fat transfer include the presence of any disease processes that adversely affect wound healing, and poor overall health status of the individual.

    WARNINGS

    REVOLVE™ System must be used within the same surgical procedure. Reuse of this device in the same patient in a subsequent surgical procedure, or for more than one patient, may result in infection and/or transmission of communicable diseases. Do not use the product if sterile packaging is damaged.

    This device will not, in and of itself, produce significant weight reduction. This device should be used with extreme caution in patients with chronic medical conditions such as diabetes, heart, lung, or circulatory system disease or obesity. The volume of blood loss and endogenous body fluid loss may adversely affect intra and/or postoperative hemodynamic stability and patient safety. The capability of providing adequate, timely replacement is essential for patient safety.

    PRECAUTIONS

    REVOLVE™ System is designed to remove localized deposits of excess fat through small incision and subsequently transfer the tissue back to the patient. Use of this device is limited to those physicians who, by means of formal professional training or sanctioned continuing medical education (including supervised operative experience), have attained proficiency in suction lipoplasty and tissue transfer. Results of this procedure will vary depending upon patient age, surgical site, and experience of the physician. Results of this procedure may or may not be permanent. The amount of fat removed should be limited to that necessary to achieve a desired cosmetic effect. Filling the device with adipose tissue over the maximum fill volume line can lead to occlusion of the mesh resulting in mesh tear.

    ADVERSE EFFECTS

    Some common adverse effects associated with autologous fat transfer are asymmetry, over- and/or under-correction of the treatment site, tissue lumps, bleeding, and scarring. Potential adverse effects associated with REVOLVE™ System include fat necrosis, cyst formation, infection, chronic foreign body response, allergic reaction, and inflammation.

    REVOLVE™ System is available by prescription only.

    For more information, please see the Instructions for Use (IFU) and User Manual for REVOLVE™ System.

    To report an adverse reaction, please call Allergan at 1.800.367.5737.


    SkinMedica®

    SkinMedica® is a physician-dispensed, cosmetic, and non-prescription skin care product line.

    Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

    SkinMedica® Total Defense + Repair Broad Spectrum Sunscreens (SPF 34, SPF 34 Tinted, and SPF 50+) and Essential Defense Broad Spectrum Sunscreens (Everyday Clear SPF 47, Mineral Shield Tinted SPF 32, and Mineral Shield SPF 35) are over -the-counter drug products which are formulated and marketed pursuant to FDA’s governing regulations set forth at 21 C.F.R. Part 352.

    The PA rating System is used in Japan to classify UVA protection and is not an FDA requirement on sunscreens sold in the U.S.

    SkinMedica® Acne System, Acne Treatment Lotion, Purifying Foaming Wash, and Purifying Toner, are over -the-counter drug products which are formulated and marketed pursuant to FDA’s governing regulations set forth at 21 C.F.R. Part 333 Subpart D.


    DiamondGlow™ Treatment Important Information

    Indication and Use

    The DiamondGlow™ device is indicated for general dermabrasion of the skin and also delivers topical cosmetic serums onto the skin.

    IMPORTANT SAFETY INFORMATION

    DiamondGlow™ is contraindicated in patients who have compromised skin quality including but not limited to, sunburned, chapped, irritated or broken skin, open wounds, active, weeping acne, cold sores, or herpetic ulcers. Ask your patient if they are pregnant or lactating or if they have any medical conditions, including allergies, and usage of topical medication on the area to be treated.

    Typical side effects include a scratchy, stinging sensation during the treatment and temporary tightness, redness or slight swelling after the treatment. Rare serious side effects may also occur and include severe skin irritation and allergic reactions. Cease use of the device immediately if any of these serious side effects are observed.

    Patients should be advised to use a sunscreen with a sun protection factor of 30 or higher following treatment.

    Consult the DiamondGlow™ User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects.


    SkinMedica® Pro-Infusion Serums Disclaimer

    SkinMedica® Pro-Infusion Serums are intended to meet the FDA’s definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These products are not intended to be drugs that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

    This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). Read More
    This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). By clicking “Accept” you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above.

    You can still use this website if you do not click “Accept,” but your experience may be different.

    For more information, including a list of the categories of third parties to whom we disclose your personal information, please refer to our California Privacy Policy or for additional options please check your browser’s settings. Read Less